drugset
drugset / Trial / NCT04559412

Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

NCT04559412 ↗

Phase 1 Unknown 11 enrolled Sorrento Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label pilot study in patients with rheumatoid arthritis (RA). All patients will receive SOFUSA Enbrel 25 mg once weekly. The dose will be increased to 50 mg if the dose escalation criteria are met during the dose escalation phase of the study.

Timeline

Start
2021-03-15
Primary completion
2024-01
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg —
Subject Etanercept Protein / enzyme biologic 50 mg —

Indications

rheumatoid arthritis